Curis (CRIS) SEC Filings: History & Chart

Curis, Inc.(CRIS)

Biotechnology · Lexington, MA

$0.76-0.03 (-3.43%)

Delayed quote: Oct 6, 2026, 11:17 AM EDT

About Curis, Inc.

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company’s pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small-molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreements with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed three programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.

Lexington, MA

22 employees

www.curis.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: James Dentzer

View full financials

Form	Filing Date	Accepted	Document
424B4	Aug 13, 2026	Aug 13, 2026	View filing
EFFECT	Aug 12, 2026	Aug 13, 2026	View filing
S-1	Aug 10, 2026	Aug 10, 2026	View filing
8-K	Jul 30, 2026	Jul 30, 2026	View filing
4	Jul 9, 2026	Jul 9, 2026	View filing
4	Jul 9, 2026	Jul 9, 2026	View filing
4	Jul 9, 2026	Jul 9, 2026	View filing
4	Jul 9, 2026	Jul 9, 2026	View filing
4	Jul 9, 2026	Jul 9, 2026	View filing
4	Jul 9, 2026	Jul 9, 2026	View filing
4	Jul 9, 2026	Jul 9, 2026	View filing
4	Jul 9, 2026	Jul 9, 2026	View filing
8-K	Jul 2, 2026	Jul 2, 2026	View filing
8-K/A	Jul 1, 2026	Jul 1, 2026	View filing
8-K	Jul 1, 2026	Jul 1, 2026	View filing
8-K	Jun 25, 2026	Jun 25, 2026	View filing
DEF 14A	Jun 5, 2026	Jun 5, 2026	View filing
PRE 14A	May 22, 2026	May 22, 2026	View filing
8-K	May 22, 2026	May 22, 2026	View filing
SC 13G/A	May 15, 2026	May 15, 2026	View filing
SC 13G/A	May 14, 2026	May 14, 2026	View filing
10-Q	May 13, 2026	May 13, 2026	View filing
8-K	May 12, 2026	May 12, 2026	View filing
8-K	May 1, 2026	May 1, 2026	View filing
SC 13G	Apr 24, 2026	Apr 24, 2026	View filing
ARS	Apr 21, 2026	Apr 21, 2026	View filing
DEF 14A	Apr 21, 2026	Apr 21, 2026	View filing
PRE 14A	Apr 10, 2026	Apr 10, 2026	View filing
SC 13G/A	Apr 7, 2026	Apr 7, 2026	View filing
SC 13G	Apr 7, 2026	Apr 7, 2026	View filing

SEC Filings

Recent Filings